NeOnc Technologies Holdings Inc Dossier
Qualitative Analysis
Business overview
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of central nervous system (CNS) therapeutics. The company's proprietary NEO™ drug development platform is designed to address the persistent challenges of delivering therapeutics across the blood-brain barrier (BBB). Its lead product candidates include NEO100, a highly purified form of perillyl alcohol administered via intranasal inhalation to bypass the BBB, and NEO212, an oral chemical conjugate combining the chemotherapeutic drug temozolomide with perillyl alcohol. NeOnc has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California (USC) to protect its pipeline.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding clinical development footprint and infrastructure into the GCC and MENA regions through local subsidiaries NuroMENA and NuroCure in Abu Dhabi, supported by parallel regulatory filings and clinical trial execution.
Expected impact: Accelerates global therapeutic development of NEO100 and NEO212 by running parallel clinical trials across multiple international jurisdictions.
Advancing lead clinical candidates NEO100 (intranasal perillyl alcohol) and NEO212 (oral perillyl alcohol-temozolomide conjugate) to deliver chemotherapy agents directly across the blood-brain barrier for central nervous system cancers.
Expected impact: Provides novel, less toxic, and highly effective treatment options for patients with aggressive brain tumors like glioblastoma and brain metastases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of an IP portfolio featuring artificial intelligence-driven drug discovery tools, rapid magnetic 3D bioprinting technology, and quantum molecular modeling capabilities (including U.S. Patent No. 11,788,057 B2). The technology allows NeOnc to create patient-derived 3D brain tumor models to accelerate preclinical drug discovery and high-throughput screening.
Financial impact: Valued at $3.5 million, consisting of $500,000 in cash and $3.0 million in NeOnc common stock issued at $25.00 per share.
Strategic Partnerships
Establishes a robust clinical and operational presence in the UAE and broader MENA region. Quazar leads a capital formation round to fund regional clinical trials and build critical infrastructure through Abu Dhabi-based subsidiaries NuroMENA and NuroCure.
Terms: A definitive agreement for a $50 million strategic partnership, priced at $25.00 per share. Quazar acquires 1.4 million shares of NeOnc for a $35 million anchor position, with the remaining $15 million earmarked for regional Phase 2B clinical trials and infrastructure.
Provides institutional validation and essential capital to strengthen the balance sheet, repay outstanding indebtedness, and fund ongoing clinical trials for NEO100 and NEO212.
Terms: Anchored by a $10 million commitment from Cinctive Capital as part of a larger PIPE transaction of up to approximately $16 million, purchasing common stock and warrants at a combined price of $7.20 per share.